Correction: Mutation Scanning Using MUT-MAP, a High-Throughput, Microfluidic Chip-Based, Multi-Analyte Panel
Rajesh Patel, Alison Tsan, Rachel Tam et al. · PLoS ONE · 2013
Targeted anticancer therapies rely on the identification of patient subgroups most likely to respond to treatment.Predictive biomarkers play a key role in patient selection, while diagnostic and prognostic biomarkers expand our understanding of tumor biology, suggest treatment combinations, and facilitate discovery of novel drug targets.We have developed a highthroughput microfluidics method for mutation detection (MUT-MAP, mutation multi-analyte panel) based on TaqMan or allele-specific PCR (AS-PCR) assays.We analyzed a set of 71 mutations across six genes of therapeutic interest.The six-gene mutation panel was designed to detect the most common mutations in the EGFR, KRAS, PIK3CA, NRAS, BRAF, and AKT1 oncogenes.The DNA was preamplified using custom-designed primer sets before the TaqMan/AS-PCR assays were carried out using the Biomark microfluidics system (Fluidigm; South San Francisco, CA).A cross-reactivity analysis enabled the generation of a robust automated mutation-calling algorithm which was then validated in a series of 51 cell lines and 33 FFPE clinical samples.All detected mutations were confirmed by other means.Sample input titrations confirmed the assay sensitivity with as little as 2 ng gDNA, and demonstrated excellent inter-and intra-chip reproducibility.Parallel analysis of 92 clinical trial samples was carried out using 2-100 ng genomic DNA (gDNA), allowing the simultaneous detection of multiple mutations.DNA prepared from both fresh frozen and formalin-fixed, paraffin-embedded (FFPE) samples were used, and the analysis was routinely completed in 2-3 days: traditional assays require 0.5-1 mg high-quality DNA, and take significantly longer to analyze.This assay can detect a wide range of mutations in therapeutically relevant genes from very small amounts of sample DNA.As such, the mutation assay developed is a valuable tool for high-throughput biomarker discovery and validation in personalized medicine and cancer drug development.
Cited by 8 works. doi:10.1371/annotation/2bf00719-6566-4ef0-8f75-e4895309b84a Open-access PDF
Authors
- Rajesh Patel
- Alison Tsan
- Rachel Tam
- Rupal M. Desai
- Jill M. Spoerke
- Nancy Schoenbrunner
- Keith Bauer
- Rajiv G. Raja
References
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)
- COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- The Catalogue of Somatic Mutations in Cancer (COSMIC)
- Rapid, nonradioactive detection of mutations in the human genome by allele-specific amplification.
- The cancer biomarker problem
- Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients.
- Detection of Specific Polymerase Chain Reaction Product by Utilizing the 5'→3' Exonuclease Activity of Thermus aquaticus DNA Polymerase